BioSpace News Archive

Growing prevalence of dental disorders among a considerable population is driving the market revenue growth.

Factors contributing to the growth of the defibrillator market share are; increase in implementation of technologically advanced defibrillators, upward demand for superiority medical care and cardiovascular.

High disease prevalence across the globe coupled with ongoing research & development is expected to stimulate market growth.

Rising government funding for clinical trials, increased application of software solutions in clinical trials and clinical research, the growing customer base for e-Clinical solutions, are key factors contributing to the high CAGR of eClinical Solutions during the forecast period.

Rising prevalence of cardiovascular disorders, growing awareness about early diagnosis of heart diseases, and increasing investments in research and development activities are key factors boosting global market growth.

Advancements in software security systems, ongoing research activities, and private and government investments.

The rising demand for ambulatory infusion pumps in home care settings, coupled with the increasing incidence of chronic diseases is some of the major factors driving the growth of the market.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab

ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ASC618, an investigational second-generation gene therapy for patients with severe and moderately severe hemophilia A.

IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions.